[바이오사 리포트] 오스코텍, 로열티로 외형 확대…2Q 마일스톤 분기점

Oscotec is transitioning to a commercial-stage biotech company powered by Lazertinib royalties, but faces an immediate profitability test as R&D spending still exceeds revenue growth. The Q2 European commercialization milestone and early pipeline licensing-out strategies will be critical validators for whether initial cash inflows can sustain operations and fund next-generation cancer drug development.